샘플 요청 목록

 카트 문의
시장보고서
상품코드
1784014

세계의 폐렴구균 백신 시장

Pneumococcal Vaccines
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 285 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

폐렴구균 백신 세계 시장은 2030년까지 113억 달러에 달할 전망

2024년에 83억 달러로 추정되는 폐렴구균 백신 세계 시장은 2024-2030년 분석 기간 동안 CAGR 5.3%로 성장하여 2030년에는 113억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 폐렴구균 결합 백신은 CAGR 6.2%를 기록하며 분석 기간 종료시에는 74억 달러에 달할 것으로 예측됩니다. 폐렴구균 다당체 백신 분야의 성장률은 분석 기간 동안 CAGR 3.6%로 추정됩니다.

미국 시장은 23억 달러, 중국은 CAGR 8.5%로 성장할 것으로 예측

미국의 폐렴구균 백신 시장은 2024년에는 23억 달러에 달할 것으로 추정됩니다. 세계 2위 경제 대국인 중국은 2024년부터 2030년 분석 기간 동안 CAGR 8.5%로 성장하여 2030년에는 시장 규모가 23억 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.5%와 5.3%로 예측됩니다. 유럽에서는 독일이 CAGR 약 3.4%로 성장할 것으로 예측됩니다.

폐렴구균 백신 세계 시장 - 주요 동향과 촉진요인 정리

폐렴구균 백신이 공중 보건에 중요한 이유는 무엇인가?

폐렴구균 백신 폐렴구균 백신은 폐렴, 수막염, 패혈증 등 심각한 질환의 원인균인 폐렴구균에 의한 감염증을 예방하는 데 필수적입니다. 이러한 감염은 특히 영유아, 유아, 노약자, 면역력이 약한 환자들에게 심각한 건강 위험을 초래합니다. 폐렴구균 백신의 보급으로 전 세계적으로 폐렴구균 관련 사망률과 이환율이 크게 감소하고 있으며, 전 세계 예방접종 프로그램에서 그 중요성이 커지고 있습니다.

세계보건기구(WHO)와 질병통제예방센터(CDC)를 포함한 각국 정부와 의료 기관은 취약 계층을 보호하기 위해 폐렴구균 백신의 정기적인 접종을 강력히 권고하고 있습니다. 고소득 국가와 개발도상국의 국가 예방접종 프로그램은 폐렴구균 결합형 백신(PCV)과 폐렴구균 다당질 백신(PPSV)의 보급을 가속화하여 감염률을 크게 낮추고 있습니다. 또한, COVID-19 팬데믹으로 호흡기 감염에 대한 인식이 높아지면서 COVID-19 환자의 세균성 폐렴으로 인한 합병증을 줄이기 위한 광범위한 공중보건 이니셔티브의 일환으로 폐렴구균 백신 접종에 대한 수요가 증가하고 있습니다.

백신 개발의 기술 혁신은 시장을 어떻게 변화시키고 있는가?

폐렴구균 백신 시장은 생명공학, 백신 제제, 예방접종 전략의 발전으로 빠르게 발전하고 있습니다. 가장 중요한 혁신 중 하나는 더 넓은 혈청형을 커버하는 차세대 폐렴구균 결합형 백신(PCV)의 개발입니다. 화이자, 머크, 글락소 스미스클라인(GSK) 등 주요 백신 제조사들은 항생제 내성 및 백신 비내성 혈청형의 출현에 대응하기 위해 확장된 폐렴구균 균주에 대한 방어력을 제공하는 다가 PCV를 출시하고 있습니다.

예를 들어, 화이자의 PREVNAR 20과 머크의 VAXNEUVANCE(PCV15)는 중증 감염을 유발하는 폐렴구균 균주에 대한 면역력 강화를 위해 설계된 차세대 백신입니다. 이러한 백신은 PREVNAR 13이나 PCV10과 같이 적은 수의 혈청형에 대한 방어력을 제공하는 기존 백신에 비해 큰 진전을 이루었습니다. 또한, 다양한 폐렴구균 균주에 대해 보다 광범위하고 지속적인 면역을 제공하기 위한 단백질 기반 연구도 활발히 진행되고 있습니다.

폐렴구균 백신 연구에서의 mRNA 백신 기술의 통합도 시장을 크게 변화시키는 발전입니다. mRNA 백신 COVID-19의 성공에 영감을 받아 각 업체들은 개발 기간 단축, 효능 향상, 새로운 혈청형에 대한 적응성을 제공할 수 있는 mRNA 기반 백신을 연구하고 있습니다. 이러한 기술 혁신은 특히 질병 부담이 큰 지역에서 폐렴구균 감염 예방에 혁명을 일으킬 수 있는 잠재력을 가지고 있습니다.

전 세계적으로 폐렴구균 백신 접종에 대한 수요가 증가하는 이유는 무엇일까?

예방접종 프로그램의 확대, 인구 고령화, 호흡기 감염에 대한 인식이 높아지면서 폐렴구균 백신에 대한 수요가 전 세계적으로 증가하고 있습니다. 아프리카, 남아시아, 라틴아메리카 등 영아 사망률이 높고 폐렴구균 감염 부담이 큰 국가에서는 Gavi, Vaccine Alliance, Global Pneumococcal Vaccination Initiative(세계 폐렴구균 백신 접종 이니셔티브) 등의 기관과의 파트너십을 통해 백신 접종에 대한 노력을 확대하고 있습니다. 이러한 이니셔티브는 저소득 지역의 백신 접근성을 개선하는 것을 목표로 하고 있으며, 시장 확대에 큰 도움이 되고 있습니다.

세계 인구의 고령화는 폐렴구균 백신 접종에 대한 수요를 촉진하는 또 다른 중요한 요인입니다. 고령자, 특히 당뇨병, 만성폐쇄성폐질환(COPD), 심혈관질환 등 기저질환을 앓고 있는 노인은 폐렴구균 감염의 위험이 높습니다. 그 결과 많은 국가에서 성인용 폐렴구균 백신 접종 프로그램이 도입되어 소아기 외의 예방접종 보급이 촉진되고 있습니다. 항균제 내성 폐렴구균(AMR)의 증가로 예방백신 접종의 필요성이 더욱 강조되고 있습니다. 약제 내성 폐렴구균은 치료 옵션이 제한적이기 때문에 백신 접종이 가장 효과적인 예방책이기 때문입니다.

또한, 팬데믹 이후 호흡기 건강에 대한 관심이 높아지면서 폐렴구균 백신 접종이 가속화되었습니다. 현재 많은 공중 보건 기관은 고위험군에게 독감 및 COVID-19 부스터와 함께 폐렴구균 백신 접종을 권장하고 있으며, 성인 정기 예방접종 프로그램에 포함되어 있습니다. 제약 업계의 투여 일정 간소화 및 1회 접종 혼합 백신(폐렴구균 백신과 독감 및 RSV 백신의 조합 등) 개발 노력은 특히 고령자 및 면역 결핍 환자의 접종을 더욱 촉진할 것으로 예상됩니다.

폐렴구균 백신 시장의 성장을 촉진하는 요인은 무엇인가?

폐렴구균 백신 시장의 성장은 기술 발전, 전 세계 예방접종률 향상, 헬스케어 투자 증가 등 여러 요인에 의해 주도되고 있습니다. 주요 원동력 중 하나는 정부 정책 및 국제적인 자금 지원 이니셔티브에 힘입어 소아 및 성인 백신 접종 프로그램을 확대하는 것입니다. 각국은 폐렴구균 백신을 정기 예방접종 일정에 포함시키고 있으며, 이는 시장의 광범위한 성장에 기여하고 있습니다.

또 다른 주요 요인은 의약품의 기술 혁신과 경쟁 제품 개발입니다. 백신 제조업체들은 진화하는 폐렴구균 균주에 대한 보다 광범위한 방어력을 제공하기 위해 지속적으로 제형을 개선하고 있습니다. 다가 PCV와 혼합 백신의 출시로 면역 지속 기간이 길어지고 부스터 용량의 필요성이 감소함에 따라 시장의 미래가 형성될 것으로 예상됩니다. 또한, 콜드체인 인프라와 백신 유통망에 대한 투자로 외딴 지역과 소외된 지역에서의 접근성이 개선되고 있습니다.

신흥 경제국의 폐렴구균성 질환 부담 증가도 수요를 촉진하고 있습니다. 인도, 중국, 브라질 등의 국가에서는 정부가 공중보건 전략의 일환으로 폐렴구균 백신 접종을 우선시하는 경향이 강화되고 있으며, 이는 보급률 증가로 이어지고 있습니다. 또한, 기업과의 제휴 및 민관협력을 통해 백신 비용을 절감하여 저소득층도 쉽게 예방접종을 받을 수 있도록 하고 있습니다.

여행과 의료관광의 성장도 시장에 영향을 미치는 요인 중 하나입니다. 많은 여행자, 특히 폐렴구균 감염이 높은 지역을 방문하는 여행자들이 예방접종을 선택하고 있으며, 선진국과 개발도상국 모두에서 수요가 증가하고 있습니다.

백신 기술의 지속적인 기술 혁신, 폐렴구균 감염 예방에 대한 인식 제고, 정부와 민간 부문의 강력한 지원으로 폐렴구균 백신 시장은 꾸준히 확대될 태세를 갖추고 있습니다. 전 세계 보건의료의 우선순위가 예방의료와 예방접종으로 계속 이동하고 있는 가운데, 폐렴구균 백신은 앞으로도 전 세계 감염병 예방의 핵심이 될 것입니다.

부문

백신 유형(폐렴구균 결합 백신, 폐렴구균 다당체 백신), 제품 유형(Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil, 기타 제품 유형)

조사 대상 기업 사례

  • AIM Vaccine Co., Ltd.
  • AstraZeneca
  • Beijing Minhai Biotechnology Co., Ltd.
  • Bharat Biotech International Ltd.
  • Biological E. Limited
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc(GSK)
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sinopharm Group Co., Ltd.
  • Sinovac Biotech Ltd.
  • Vaxcyte, Inc.
  • Walvax Biotechnology Co., Ltd.

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴로 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.08.11

Global Pneumococcal Vaccines Market to Reach US$11.3 Billion by 2030

The global market for Pneumococcal Vaccines estimated at US$8.3 Billion in the year 2024, is expected to reach US$11.3 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Pneumococcal Conjugate Vaccine, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$7.4 Billion by the end of the analysis period. Growth in the Pneumococcal Polysaccharide Vaccine segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 8.5% CAGR

The Pneumococcal Vaccines market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 8.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Pneumococcal Vaccine Market - Key Trends & Drivers Summarized

Why Is the Pneumococcal Vaccine Critical for Public Health?

Pneumococcal vaccines are essential in preventing infections caused by Streptococcus pneumoniae, a bacterium responsible for serious diseases such as pneumonia, meningitis, and sepsis. These infections pose a significant health risk, particularly to infants, young children, elderly individuals, and immunocompromised patients. The widespread adoption of pneumococcal vaccines has led to a substantial reduction in pneumococcal-related mortality and morbidity worldwide, reinforcing their importance in global immunization programs.

Governments and healthcare organizations, including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), strongly advocate for routine pneumococcal vaccination to protect vulnerable populations. National immunization programs in high-income and developing countries have accelerated the uptake of pneumococcal conjugate vaccines (PCVs) and pneumococcal polysaccharide vaccines (PPSVs), significantly lowering infection rates. Additionally, the COVID-19 pandemic heightened awareness of respiratory infections, leading to increased demand for pneumococcal vaccination as part of broader public health initiatives to reduce complications from bacterial pneumonia in COVID-19 patients.

How Are Innovations in Vaccine Development Transforming the Market?

The pneumococcal vaccine market has evolved rapidly due to advancements in biotechnology, vaccine formulations, and immunization strategies. One of the most significant innovations is the development of next-generation pneumococcal conjugate vaccines (PCVs) with broader serotype coverage. Leading vaccine manufacturers, including Pfizer, Merck, and GlaxoSmithKline (GSK), have introduced multi-valent PCVs that offer protection against an expanded range of pneumococcal strains, addressing the challenge of emerging antibiotic-resistant and non-vaccine serotypes.

For instance, Pfizer’s PREVNAR 20 and Merck’s VAXNEUVANCE (PCV15) are next-generation vaccines designed to provide enhanced immunity against pneumococcal strains responsible for severe infections. These vaccines represent a major advancement over older formulations such as PREVNAR 13 and PCV10, which offered protection against fewer serotypes. Additionally, research into protein-based pneumococcal vaccines is gaining momentum, aiming to provide broader and more durable immunity against diverse pneumococcal strains.

Another transformative development in the market is the integration of mRNA vaccine technology in pneumococcal vaccine research. Inspired by the success of mRNA COVID-19 vaccines, companies are exploring mRNA-based pneumococcal vaccines that could offer quicker development timelines, improved efficacy, and adaptability against emerging serotypes. Such innovations have the potential to revolutionize pneumococcal disease prevention, especially in regions with high disease burdens.

Why Is Global Demand for Pneumococcal Vaccination Increasing?

The demand for pneumococcal vaccines is rising globally due to expanding immunization programs, aging populations, and increased awareness of respiratory infections. Countries with high infant mortality rates and a high burden of pneumococcal disease, such as those in Africa, South Asia, and Latin America, are scaling up vaccination efforts through partnerships with organizations like Gavi, the Vaccine Alliance, and the Global Pneumococcal Vaccination Initiative. These initiatives aim to improve vaccine access in low-income regions, significantly driving market expansion.

The aging global population is another critical factor fueling demand for pneumococcal vaccination. Older adults, especially those with underlying health conditions such as diabetes, chronic obstructive pulmonary disease (COPD), and cardiovascular diseases, face a heightened risk of pneumococcal infections. As a result, many countries have introduced adult pneumococcal vaccination programs, encouraging widespread immunization beyond childhood schedules. The rising prevalence of antimicrobial resistance (AMR) has further emphasized the need for preventive vaccination, as drug-resistant pneumococcal strains limit treatment options, making vaccination the most effective defense.

Additionally, the post-pandemic focus on respiratory health has accelerated pneumococcal vaccine uptake. Many public health agencies now recommend pneumococcal vaccination alongside flu and COVID-19 boosters for high-risk populations, integrating it into routine adult immunization programs. The pharmaceutical industry’s efforts to simplify dosing schedules and develop single-dose combination vaccines (e.g., pneumococcal vaccines combined with influenza or RSV vaccines) are expected to further drive uptake, particularly among elderly patients and immunocompromised individuals.

What Factors Are Driving the Growth of the Pneumococcal Vaccine Market?

The growth in the pneumococcal vaccine market is driven by several factors, including technological advancements, increasing global immunization coverage, and rising healthcare investments. One of the primary drivers is the expansion of pediatric and adult vaccination programs, supported by government policies and international funding initiatives. Countries are incorporating pneumococcal vaccines into routine immunization schedules, contributing to widespread market growth.

Another key factor is pharmaceutical innovation and competitive product development. Vaccine manufacturers are continuously enhancing their formulations to provide broader protection against evolving pneumococcal strains. The launch of multi-valent PCVs and combination vaccines is expected to shape the future of the market, offering longer-lasting immunity and reduced booster dose requirements. Additionally, investments in cold chain infrastructure and vaccine distribution networks are improving access to pneumococcal vaccines in remote and underserved regions.

The rising burden of pneumococcal diseases in emerging economies is also driving demand. Governments in countries like India, China, and Brazil are increasingly prioritizing pneumococcal vaccination as part of their public health strategies, leading to higher adoption rates. Additionally, corporate partnerships and public-private collaborations are helping reduce vaccine costs, making immunization more affordable for lower-income populations.

The growth of travel and medical tourism is another factor influencing the market. Many travelers, particularly those visiting regions with high pneumococcal disease prevalence, are opting for preventive vaccination, increasing demand in both developed and developing countries.

With ongoing innovations in vaccine technology, increasing awareness of pneumococcal disease prevention, and strong government and private sector support, the pneumococcal vaccine market is poised for steady expansion. As global healthcare priorities continue to shift toward preventive care and immunization, pneumococcal vaccines will remain a cornerstone of infectious disease prevention worldwide.

SCOPE OF STUDY:

The report analyzes the Pneumococcal Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine); Product Type (Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil, Other Product Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • AIM Vaccine Co., Ltd.
  • AstraZeneca
  • Beijing Minhai Biotechnology Co., Ltd.
  • Bharat Biotech International Ltd.
  • Biological E. Limited
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc (GSK)
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sinopharm Group Co., Ltd.
  • Sinovac Biotech Ltd.
  • Vaxcyte, Inc.
  • Walvax Biotechnology Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Pneumococcal Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Pneumonia and Invasive Pneumococcal Disease Drives Demand for Widespread Immunization
    • Expansion of National Immunization Programs in Emerging Markets Strengthens Routine Pediatric Vaccine Uptake
    • Aging Population and Increased Comorbidity Risk Spur Adult and Geriatric Pneumococcal Vaccination Campaigns
    • Introduction of Conjugate Vaccines With Broader Serotype Coverage Enhances Preventive Effectiveness and Adoption
    • WHO and GAVI-Led Global Health Initiatives Expand Access to Pneumococcal Vaccines in Low-Income Countries
    • Pharmaceutical Innovation in Multivalent and Next-Gen Pneumococcal Vaccines Drives Market Differentiation
    • Combination Vaccines With DTP or Influenza Components Simplify Immunization Schedules and Improve Adherence
    • Rising Antimicrobial Resistance Concerns Amplify Preventive Role of Vaccines in Reducing Bacterial Infections
    • Increased Investment in Cold Chain Infrastructure Enhances Vaccine Storage and Distribution in Remote Areas
    • Private Sector Expansion of Adult Vaccine Clinics and Retail Pharmacies Boosts Urban Accessibility
    • Regulatory Acceleration and Fast-Track Approvals Speed Up Introduction of New Vaccine Candidates
    • Serotype Replacement and Regional Epidemiology Trends Influence Market Dynamics and R&D Priorities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pneumococcal Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pneumococcal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Pneumococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pneumococcal Conjugate Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pneumococcal Conjugate Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Pneumococcal Conjugate Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Pneumococcal Polysaccharide Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Pneumococcal Polysaccharide Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Pneumococcal Polysaccharide Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Prevnar 13 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Prevnar 13 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Prevnar 13 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Synflorix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Synflorix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Synflorix by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pneumovax 23 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pneumovax 23 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Pneumovax 23 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Vaxneuvance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Vaxneuvance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Vaxneuvance by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pneumosil by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Pneumosil by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Pneumosil by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • CHINA
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Pneumococcal Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Pneumococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • FRANCE
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Pneumococcal Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Pneumococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • INDIA
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Pneumococcal Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Pneumococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Pneumococcal Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Pneumococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030
  • AFRICA
    • Pneumococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Pneumococcal Vaccines by Vaccine Type - Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Pneumococcal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Pneumococcal Vaccines by Product Type - Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Pneumococcal Vaccines by Product Type - Percentage Breakdown of Value Sales for Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil and Other Product Types for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제